NVO logo

NVO
Novo Nordisk A/S

31,272
Mkt Cap
$151.48B
Volume
9.29M
52W High
$81.44
52W Low
$35.12
PE Ratio
10.54
NVO Fundamentals
Price
$44.19
Prev Close
$44.96
Open
$44.74
50D MA
$40.56
Beta
0.93
Avg. Volume
16.66M
EPS (Annual)
$3.49
P/B
6.38
Rev/Employee
$679,358.45
$242,651.58
Loading...
Loading...
News
all
press releases
Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth?
Novo Nordisk's EU label expansions may widen semaglutide use and boost volumes, but pricing pressure and Lilly rivalry can limit recovery.
News Placeholder
More News
News Placeholder
AMGN Stock Down 13% in 3 Months: Buy the Dip or Book Profits?
Amgen faces LOE headwinds and pricing pressure, yet key growth drugs and biosimilars continue gaining traction.
News Placeholder
4 Large-Cap Pharma Stocks to Buy as Industry Recovery Accelerates
In the Large-Cap Pharmaceuticals industry, LLY, J&J, NVO and BAYRY are worth retaining as the industry shows some recovery.
News Placeholder
Beat the Market the Zacks Way: ORIX, Starbucks, Alphabet in Focus
IX, SBUX and GOOGL rallied after Zacks upgrades and portfolio additions, while major indexes stayed volatile amid Fed and inflation concerns.
News Placeholder
Eli Lilly Stock Eyes Best Month This Year As Cholesterol, Obesity Drug Tailwinds Build
LLY's stock is still down year-to-date as AI-driven narratives have captured the bulk of investor attention and capital in 2026.
News Placeholder
CHMP Backs EU Approval of Novo Nordisk's Wegovy Pill for Obesity
NVO's Wegovy pill gets CHMP backing, moving it closer to becoming the first oral GLP-1 treatment approved in the EU for weight management.
News Placeholder
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
News Placeholder
Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know.
Key PointsEli Lilly and Novo Nordisk have been vying for dominance in the weight loss drug market...
News Placeholder
LLY Reports Third Phase III Win for Next-Generation Obesity Drug
Eli Lilly's retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader gains across obesity-related measures.
News Placeholder
HIMS Stock Extends 3-Day Rally: Hims & Hers Targets GLP-1 Gold Rush In Canada After Novo Nordisk Patent Expiry
The launch follows Novo Nordisk’s failure to pay a C$250 patent maintenance fee in Canada.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available